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Background: The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in
more than 90% of patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC in the BCC
Outcomes with LDE225 Treatment study.
Objective: This report provides long-term follow-up data collected up to 12 months after the last patient
was randomized.
Methods: In this multicenter, randomized, double-blind phase II study, patients were randomized 1:2 to
sonidegib 200 or 800 mg. The primary end point was objective response rate assessed by central review.
Results: Objective response rates in the 200- and 800-mg arms were 57.6% and 43.8% in locally advanced
BCC and 7.7% and 17.4% in metastatic BCC, respectively. Among the 94 patients with locally advanced BCC
who responded, only 18 progressed or died and more than 50% had responses lasting longer than
6 months. In addition, 4 of 5 responders with metastatic BCC maintained an objective response. Grade 3/4
adverse events and those leading to discontinuation were less frequent with sonidegib 200 versus 800 mg
(38.0% vs 59.3%; 27.8% vs 37.3%, respectively).
Limitations: No placebo or comparator arms were used because sonidegib demonstrated efficacy in
advanced BCC in a phase I study, and the hedgehog pathway inhibitor vismodegib was not yet approved.
Conclusion: With longer follow-up, sonidegib demonstrated sustained tumor responses in patients with
advanced BCC. ( J Am Acad Dermatol 2016;75:113-25.)
Key words: advanced basal cell carcinoma; Basal Cell Carcinoma Outcomes with LDE225 Treatment study;
hedgehog pathway inhibitor; locally advanced basal cell carcinoma; metastatic basal cell carcinoma;
sonidegib.
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Basal cell carcinoma (BCC), the most commonly
diagnosed cancer,1,2 is associated with aberrant activa-
tion of hedgehog signaling caused by sporadic muta-
tions in the pathway components patched ([85% of
cases) and smoothened
(z10%).3-5 The vast majority
of BCCs are effectively treated
with topical therapy, surgery,
and/or radiotherapy,6-8 but in
a minority (\1%) of patients,
BCCs can become advanced
and difficult to treat.9 For
patients with advanced BCC,
including those with locally
advanced BCC (laBCC)
whomay havemultiple, large,
neglected, poorly defined,
aggressive, and/or recurrent
lesions that are not amenable
to surgery/radiation and
those with metastatic BCC
(mBCC), treatment options are limited1,10 and include
the oral hedgehogpathway inhibitors (HPIs) sonidegib
and vismodegib,11-17 more conventional chemo-
therapy, radiation (mBCC), or a clinical trial.6-8
Sonidegib (LDE225) is an oral HPI that selectively
targets the pathway activator smoothened, thereby
inhibitinghedgehogpathway
signaling.18,19 Sonidegib
(200 mg) was approved for
use in patients with advanced
BCC11,12 or laBCC13,14 who
are not amenable to curative
surgery/radiotherapy based
on the meaningful, durable
tumor responses observed in
the BCC Outcomes with
LDE225 Treatment (BOLT)
study.20 The primary end
point, objective response
rate (ORR), was met in both
treatment arms at the time of
the primary analysis (June 28,
2013, cutoff).20 Updated
safety and efficacy data from the 12-month analysis
(December 31, 2013, cutoff) are presented.
CAPSULE SUMMARY
d Hedgehog pathway inhibition is one of
the few treatment options available for
patients with advanced basal cell
carcinoma.
d Sonidegib provides meaningful tumor
shrinkage and durable responses in
patients with advanced basal cell
carcinoma.
d Sonidegib may offer a promising new
treatment option for this difficult-to-
treat patient population.
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METHODS
Trial design and patient eligibility
BOLT, a multicenter (58 centers, 12 countries),
randomized, double-blind, phase II study (NCT
01327053), evaluated once-daily doses of sonidegib
200 or 800 mg.20 Adults with either histologically
confirmed laBCC not amenable to radiotherapy or
curative surgery or mBCC, who had adequate organ
function and a World Health Organization (WHO)21
performance status less than or equal to 2, were
eligible. Patients previously treated with HPIs were
excluded.
Patients were randomized 1:2 to the 200-mg
(lowest efficacious dose19) and 800-mg (highest
well-tolerated, once-daily dose19) treatment arms
based on the prediction that the 800-mg dose
would be more efficacious: phase I data indicated
dose- and exposure-dependent inhibition of
glioma-associated oncogene-1 (biomarker for
hedgehog pathway activity).19 Patients were strati-
fied based on disease (laBCC vs mBCC), histologic
subtype for laBCC (aggressive vs nonaggressive),
and geographic region. Patients were randomized
by an independent provider using the central
Interactive Response Technology system (Cenduit,
Allentown, PA), and all involved in the study were
blinded until the time of the primary analysis.20 The
independent ethics committee or institutional re-
view board for each center approved the study
protocol, and each patient provided informed con-
sent before enrollment.
Outcomes
The primary end point was ORReproportion of
patients with a best overall response of complete
or partial responseeper central review. Secondary
end points included ORR by investigator review;
complete response rate, time to tumor response,
duration of response, and progression-free sur-
vival by central and investigator review; and
safety. End points were assessed using data
collected up to 12 months after the last patient
was randomized.
Study intervention and assessments
Patients were treated with sonidegib on a once-
daily continuous schedule until disease progres-
sion, intolerable toxicity, withdrawal of consent,
death, discontinuation, or study termination. Tumor
assessments were performed at baseline, during
treatment/posttreatment follow-up (weeks 5 and 9,
followed by every 8 weeks during year 1, and every
12 weeks thereafter), and at discontinuation ac-
cording to BCC-modified Response Evaluation
Criteria in Solid Tumors (mRECIST) for laBCC and
Response Evaluation Criteria in Solid Tumors
(RECIST) v1.122 for mBCC. Complete and partial
responses required confirmation on repeated as-
sessments at visits greater than or equal to 4 weeks
apart. The potential for posttreatment ulceration,
cyst formation, scarring/fibrosis, and ill-defined
lesion borders renders RECIST v1.122 inadequate
for tumor assessment in patients with laBCC. BCC-
mRECIST is a stringent composite multimodal
assessment tool that integrates magnetic resonance
imaging per RECIST v1.122 (response: $30% reduc-
tion in the sum of longest diameters of target
lesions), standard and annotated color photography
per bidimensional WHO guidelines21 (response:
$50% reduction in the sum of products of perpen-
dicular diameters of target lesions), and histology in
multiple biopsy specimens surveying the lesion
area (Supplemental Table I). An independent re-
view committee reevaluated all central assessments
for laBCC. Fresh tumor biopsy specimens were
required to confirm a complete response and/or
when assessment was confounded by ulceration,
cyst formation and/or scarring/fibrosis. Adverse
events were monitored according to the National
Cancer Institute Common Terminology Criteria for
Adverse Events version 4.0323 from the start of
study treatment until 30 days after the last dose of
sonidegib.
Statistical methods
ORR and complete response rate with 95%
confidence intervals were estimated by treatment
arm and disease (laBCC or mBCC). Kaplan-Meier
nonparametric maximum likelihood estimate of
median time and 95% confidence intervals were
calculated for duration of response, time to tumor
response, and progression-free survival by treatment
arm and disease. Statistical testing to compare the
200- and 800-mg arms was not planned. Detailed
statistical methods of the primary analysis were
previously reported.20
Abbreviations used:
BCC: basal cell carcinoma
BOLT: Basal Cell Carcinoma Outcomes with
LDE225 Treatment
HPI: hedgehog pathway inhibitor
laBCC: locally advanced basal cell carcinoma
mBCC: metastatic basal cell carcinoma
mRECIST: modified Response Evaluation Criteria
in Solid Tumors
ORR: objective response rate
RECIST: Response Evaluation Criteria in Solid
Tumors
WHO: World Health Organization
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RESULTS
Patient baseline characteristics, disease
history, and disposition
A total of 230 patients (laBCC, n = 194; mBCC,
n = 36) enrolled in BOLT between July 20, 2011, and
January 10, 2013, were randomized into the sonide-
gib 200-mg (n = 79) or 800-mg (n = 151) treatment
arms (Fig 1). Baseline patient demographics and
disease history were similar between arms
(Supplemental Table II).20 Tumor burden at baseline
was extensive, with 62.2% of patients having 2 or
more lesions. At data cutoff for the 12-month analysis
(December 31, 2013), 77.8% of patients (73.4% vs
80.1% [200- vs 800-mg]) had discontinued treatment,
largely because of adverse events (25.3% vs 34.4%),
progressive disease (29.1% vs 9.9%), or patient
decision (8.9% vs 19.2%) (Supplemental Table III);
most discontinuations because of patient and
physician decision were because of adverse events.
Efficacy in patients with laBCC
Efficacy in patients with laBCC in the 12-month
analysis was generally similar to or improved from
that observed in the primary analysis (Figs 2 to 4;
Supplemental Fig 1; and Table I).20 Response rates
(percentage of complete and partial responses) per
central review were 57.6% and 43.8% in the 200- and
800-mg arms, respectively (Fig 2, A). Investigator-
reported response rates were higher than those
reported by central review (Fig 2, B). Disease control
Fig 1. A total of 230 patients with advanced basal cell carcinoma (BCC) were randomized to
receive once-daily doses of sonidegib 200 mg (n = 79; locally advanced BCC [laBCC], n = 66;
metastatic BCC [mBCC], n = 13) or 800 mg (n = 151; laBCC, n = 128; mBCC, n = 23). All
randomized patients were assessed for efficacy. One patient in the sonidegib 800-mg arm did
not receive treatment and therefore was not included in the safety analysis.
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rates (percentage of complete responses, partial
responses, and stable disease) were greater than
90% with sonidegib 200 mg (central, 90.9%; investi-
gator, 92.4%) and more than 80% with sonidegib
800 mg (central, 81.3%; investigator, 85.9%). Tumor
shrinkage (percentage of patients with a reduction in
the sum of the measurements of target lesion[s] per
photograph any time before data cutoff) by central
review was observed in 92.3% (Fig 3, A) and 90.1%
(Supplemental Fig 1, A) of patients treated with
sonidegib 200 and 800 mg, respectively; investiga-
tors reported similar results (Supplemental Fig 1,
Fig 2. Objective response rates (ORRs) in patients with locally advanced basal cell carcinoma
(laBCC) treated with sonidegib 200 and 800 mg. Best overall response in patients with laBCC
treated with sonidegib 200 mg (n = 66) and 800 mg (n = 128) assessed by photography,
magnetic resonance imaging, and histology according to basal cell carcinomaemodified
Response Evaluation Criteria in Solid Tumors by central (A) and investigator (B) review at the
time of the primary and 12-month analyses. Complete and partial responses required
confirmation on repeated assessments at visits greater than or equal to 4 weeks apart and
biopsy specimens were required to confirm a complete response.
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B and C ). Median time to tumor response in the 200-
and 800-mg arms was 4.0 and 3.8 months by central
review and 2.5 and 1.9 months by investigator
review, respectively (Table I). Of 94 patients
(200 mg, n = 38; 800 mg, n = 56) who responded
(central review), only 18 (19.1%; 200 mg, n = 7;
800 mg, n = 11) had disease progression or died
(Table I). The Kaplan-Meier median duration of
response by central review was not reached with
200 mg, because few responders had disease
progression or died, and was 15.7 months with
800 mg; respective median durations of response
by investigator review were 20.2 and 19.8 months
(Table I). Responses lasting more than 6 months by
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Fig 3. Waterfall plots of best change from baseline in the size of target lesions and of duration of
response in patients with locally advanced basal cell carcinoma (laBCC) per central review. Best
percentage change frombaseline in the sumof the products of perpendicular diameters in target
lesion(s) assessed by photography per World Health Organization criteria21 per central review
(A). Tumor responsewas assessed by photography, magnetic resonance imaging, and histology
according to basal cell carcinomaemodified Response Evaluation Criteria in Solid Tumors in
patients with laBCC, and best overall response is depicted by color. Assessments were excluded
from the analysis if percentage change in the size of target lesions was not available or was
contradicted by an overall lesion response of unknown. Duration of response by patient
evaluated by central review in patients responding to treatment with sonidegib 200 mg (B).
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central review were observed in 52.6% and 53.6% of
responders treatedwith 200mg (Fig 3, B) and 800mg
(data not shown), respectively.
Among patients with laBCC, 56.1% and 58.6% had
aggressive histologic subtypes of BCC (ie, micro-
nodular, infiltrative, multifocal, basosquamous, or
sclerosing) based on randomization stratification in
the 200- and 800-mg arms, respectively; nonaggres-
sive subtypes included nodular and superficial BCCs.
Response rates in patients with aggressive versus
nonaggressive subtypes per central review were
59.5% versus 55.2% in the 200-mg arm and 44.0%
versus 43.4% in the 800-mg arm, respectively; per
investigator review, the respective response rates
were 70.3% versus 72.4% (200 mg) and 54.7% versus
62.3% (800 mg).
Efficacy in patients with mBCC
In the 12-month analysis, efficacy in patients with
mBCC was generally similar to that observed in the
primary analysis (Fig 5; Supplemental Fig 2; andTable
I).20 Response rates in patients with mBCC by central
review were 7.7% and 17.4% in the 200- and 800-mg
arms, respectively (Fig 5, A); respective investigator-
reported response rates were higher (23.1% and
34.8%) (Fig 5, B). Disease control by central review
was reported in 92.3% and 91.3% of patients treated
with sonidegib 200 and 800 mg, respectively.
Investigators reported disease control in 84.6% and
82.6% of patients in the 200- and 800-mg arms. Tumor
shrinkage (by any modality) by central review was
observed in 91.7% (200 mg) and 84.2% (800 mg) of
patients (Supplemental Fig 2, A and B); investigators
reported similar results (Supplemental Fig 2,C andD).
By central review, median time to tumor response
was 1.8 and 1.0 months in the 200- and 800-mg arms,
respectively, and tumor responseswere durable,with
4 of 5 responders maintaining an objective response
(Table I). By central review, theKaplan-Meiermedian
duration of response was not reached in either arm;
by investigator review, median duration of response
was 17.7 and 10.2 months, respectively (Table I).
Safety
From the time of the primary analysis to the 12-
month analysis, the median duration of exposure
Fig 4. Images of tumor response in patients with locally advanced basal cell carcinoma
(laBCC) treated with sonidegib. A, Cheek of a 49-year-old white male patient with aggressive
laBCC treated with sonidegib 200 mg at baseline and week 61. This patient achieved an overall
partial response by central and investigator review. B, Nose of a 45-year-old white female
patient with aggressive laBCC treated with sonidegib 800 mg at baseline and week 30. This
patient achieved an overall response of stable disease by central and investigator review.
A partial response was reported at the end of treatment on day 221. Left scalp (C) and back (D)
of a 78-year-old white female patient with aggressive laBCC treated with sonidegib 800 mg
(baseline and week 21). This patient, who remained on treatment for 590 days, achieved an
overall partial response per central and investigator review.
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increased in the 200-mg arm (8.9 [range, 1.3-21.4] vs
11.0 [range, 1.3-27.8] months) and remained similar
in the 800-mg arm (6.5 [range, 0.3-19.1] vs 6.6 [range,
0.3-27.8] months). Among patients treated with
sonidegib 200 and 800 mg, 68.4% and 43.3% of
patients, respectively, remained on treatment for
8 months or longer.
The safety profile of sonidegib remained similar
between the primary and 12-month analyses.20
Nearly all patients (200 mg, 97.5%; 800 mg, 100%)
experienced 1 or more adverse events. In general,
the most common adverse events, including muscle
spasms, alopecia, dysgeusia, nausea, increased
creatine kinase, fatigue, weight loss, decreased
appetite, myalgia, and vomiting, occurred less
frequently in the 200- versus 800-mg arm (Fig 6).
Increased creatine kinase was the most common
grade 3/4 adverse event, occurring in 6.3% (200 mg)
and 13.3% (800 mg) of patients. Dose adjustment or
interruption because of adverse events was required
in 38.0% and 64.0% of patients, and discontinuation
because of adverse events occurred in 27.8%
(200 mg) and 37.3% (800 mg) of patients. The most
common adverse events leading to discontinuation
Table I. Efficacy of sonidegib by treatment arm
Patients with laBCC
Sonidegib 200 mg once daily
n = 66
Sonidegib 800 mg once daily
n = 128
Primary
Analysis*
12-mo
Analysisy
Primary
Analysis*
12-mo
Analysisy
Time to tumor responsez
Median (95% CI), mo
Per central review 3.9 (3.6-4.2) 4.0 (3.8-5.6) 3.7 (2.6-3.8) 3.8 (3.7-5.5)
Per investigator review 1.9 (1.8-3.7) 2.5 (1.9-3.7) 1.9 (1.2-2.0) 1.9 (1.4-2.0)
Duration of responsex
Events///responders, n/n;
median (95% CI), mo
Per central review 4/31; not reached 7/38; not reached 3/45; not reached 11/56; 15.7 (NE)
Per investigator review 10/43; 20.2 (10.1-20.2) 14/47; 20.2 (NE) 10/73; not reached 17/74; 19.8 (15.7-20.5)
Progression-free survival{
Events//, n; median (95% CI),
mo
Per central review 7; not reached 11; 22.1 (NE) 10; not reached 22; 21.5 (NE)
Per investigator review 15; 16.6 (13.7-22.0) 19; 22.0 (NE) 17; not reached 26; 21.5 (NE)
Patients with mBCC
Sonidegib 200 mg once daily
n = 13
Sonidegib 800 mg once daily
n = 23
Primary
Analysis*
12-mo
Analysisy
Primary
Analysis*
12-mo
Analysisy
Time to tumor responsez
Median (95% CI), mo
Per central review 4.6 (1.8-7.4) 1.8 (NE) 1.0 (1.0-2.1) 1.0 (1.0-2.1)
Per investigator review 1.0 (0.9-3.7) 1.0 (0.9-3.7) 2.7 (1.0-5.6) 2.7 (1.0-5.6)
Duration of responsex
Events///responders, n/n;
median (95% CI), mo
Per central review 0/2; not reached 0/1; not reached 1/4; 8.3 (NE) 1/4; not reached
Per investigator review 0/3; not reached 1/3; 17.7 (NE) 1/8; 10.2 (NE) 3/8; 10.2 (NE)
Progression-free survival{
Events//, n; median (95% CI),
mo
Per central review 4; 13.1 (5.6-13.1) 6; 13.1 (5.6-16.9) 10; 7.6 (6.2-11.1) 11; 11.1 (NE)
Per investigator review 7; 13.1 (9.2-16.6) 8; 13.1 (9.2-18.6) 6; 13.3 (NE) 10; 14.3 (11.1-20.2)
CI, Confidence interval; laBCC, locally advanced basal cell carcinoma; mBCC, metastatic basal cell carcinoma; NE, not estimable.
*Data cutoff was June 28, 2013; median follow-up was 13.9 months.
yData cutoff was December 31, 2013; median follow-up was 20.0 months.
zTime from randomization to first observed response (complete response or partial response), based on responder data only.
xTime from first observed response (complete response or partial response) until disease progression or death as a result of any cause.
//Progressive disease or death as a result of any cause.
{Time from randomization to first documented disease progression or death as a result of any cause.
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(200- vs 800-mg arm) in the 12-month analysis
included muscle spasms (5.1% vs 8.7%), dysgeusia
(3.8% vs 4.7%), nausea (3.8% vs 4.7%), and alopecia
(1.3% vs 6.0%); 59% of patients who discontinued
treatment because of adverse events had only grade
1/2 events. Serious adverse events regardless of
Fig 5. Objective response rates (ORRs) in patients with metastatic basal cell carcinoma (mBCC)
treated with sonidegib 200 and 800 mg. Best overall response in patients with mBCC treated
with sonidegib 200 mg (n = 13) and 800 mg (n = 23) assessed by computed tomography/
magnetic resonance imaging per Response Evaluation Criteria in Solid Tumors v1.122 by central
(A) and investigator (B) review at the time of the primary and 12-month analyses. Complete and
partial responses required confirmation on repeated assessments at visits greater than or equal
to 4 weeks apart. Best overall response of 1 patient changed from partial response to stable
disease in the 12-month analysis by central re-review because of identification of a new lesion
in a photograph received after the cutoff for the primary analysis (June 28, 2013).
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causality occurred in 16.5% (200 mg) and 32.7%
(800 mg) of patients; those suspected to be related to
sonidegib treatment occurred less frequently
(200 mg, 2.5%; 800 mg, 14.0%). Rhabdomyolysis
(1.3% vs 3.3%) and increased creatine kinase (1.3%
vs 2.7%) were the most common serious adverse
events (200 vs 800 mg) reported by investigators in
the 12-month analysis. None of the cases of rhabdo-
myolysis were confirmed by an independent review
and adjudication committee of experts on muscle
toxicity because renal function was not impaired in
these patients.20 At the time of data cutoff, 7 on-
treatment deaths had occurred, 3 of which occurred
after the primary analysis. All deaths occurred in the
800-mg arm and none were considered to be related
to treatment. The 3 new deaths included 1 patient
with laBCC with preexisting confounding conditions
at baseline, who died of cardiac arrest (study day
Fig 6. Advanced basal cell carcinoma. Most common adverse events, irrespective of causality,
reported in more than 20% of patients overall. Adverse events reported in patients treated with
sonidegib 200 mg (n = 79) and 800 mg (n = 150) were assessed according to the National Cancer
Institute’s Common Terminology Criteria for Adverse Events version 4.03 guidelines23 and
include adverse events occurring while on treatment and within 30 days of study drug
discontinuation. A patient with multiple occurrences of an adverse event is counted only once
in the category for that event, with the maximum severity rating reported. Adverse events are
reported by grade.
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349), and 2 patients with mBCC, who died of sepsis
(day 391) and respiratory arrest (day 433).
DISCUSSION
BOLT met its primary end point of ORR per
central review in both the 200- and 800-mg arms at
the time of the primary analysis20; with the addi-
tional 6 months of follow-up in this 12-month
analysis, sonidegib exhibited sustained efficacy in
patients with advanced BCC. Response rates
improved in patients with laBCC and remained
similar in patients with mBCC in both treatment
arms. In patients with laBCC, rates of response and
disease control were numerically higher in the 200-
mg arm than in the 800-mg arm likely because of
the better tolerability and longer duration of expo-
sure observed in patients treated with the 200-mg
dose of sonidegib. Disease control and tumor
shrinkage were observed in most patients with
laBCC and mBCC. In patients with laBCC, tumor
responses per central review were durable, with
only 18 of 94 responders progressing. With longer
follow-up, most patients were still alive without
disease progression. Efficacy of sonidegib was
similar in patients with aggressive and nonaggres-
sive histologic subtypes of laBCC.
The BCC-mRECIST tumor response criteria used
in patients with laBCC in BOLT is very stringent. In a
previously described prespecified analysis,24,25
response in patients with laBCC was reassessed
using BCC-RECIST-like criteria similar to those
used in the ERIVANCE study of vismodegib.26,27
The key distinction between the criteria is the
stringency required to achieve a complete response:
BCC-mRECIST required negative histology and a
complete response (or equivalent) by all image
modalities used in the assessment, whereas
BCC-RECIST-like required negative histology and a
complete or partial response by either magnetic
resonance imaging or photograph.24,25 This analysis
showed that the complete response rate in the
200-mg arm by central review was higher with
BCC-RECIST-like than with BCC-mRECIST (19.7%
vs 4.5%), and the response rate was similar using
both criteria (62.1% vs 57.6%). The difference in rates
of complete response demonstrates the stringency of
the response criteria used in BOLT and emphasizes
the clinical efficacy observed in patients with laBCC
treated with sonidegib.24,25
Sonidegib had an acceptable safety profile, with
generally fewer adverse events in the 200-mg arm.
Most adverse events with sonidegib treatment were
grade 1/2 and were consistent with the safety
profile of other HPIs.19,26-38 Muscle-related adverse
events, including muscle spasms and elevated
creatine kinase, were frequently observed in
BOLT and have been reported with vismodegib,
suggesting it may be a class effect.26-28,33,39,40
Importantly, comprehensive guidelines were
developed during BOLT to monitor and manage
muscle-related adverse events with dose adjust-
ments/interruptions20 and will be used in patients
treated with sonidegib moving forward.
HPIs have demonstrated efficacy in patients with
advanced BCC20,26,27; however, despite achieving a
response, some patients discontinue treatment
because of low-grade adverse events that cause
significant discomfort.20,26 In BOLT, over half of the
patients who discontinued because of adverse events
had only grade 1/2 events, withmanyof these patients
having already benefited from treatment.41
Developing plans to manage adverse events, as was
done in BOLT for muscle-related adverse events, and
educating patients on the importance of remaining on
therapy after achieving a response may help increase
duration on treatment and thus improve patient
benefit. A deeper response with HPIs may also be
achieved if used in combination with chemotherapies
or other targeted agents (eg, immune modifiers42).
In the BOLT 12-month analysis, sonidegib
continued to demonstrate sustained, clinically
meaningful responses in patients with advanced
BCC with no new safety concerns. These data, in
addition to the results from the 12-month update of
ERIVANCE,27 indicate that the approved HPIs
sonidegib and vismodegib provide durable
responses and have a manageable safety profile,
supporting a role for HPIs in the treatment of patients
with advancedBCC. Future studies designed to assess
how to optimize HPI therapy and to understand how
best to incorporate HPIs into the current treatment
algorithm for advanced BCC are warranted.
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Supplemental Fig 1. Waterfall plots of best change from baseline in the size of target lesions
in patients with locally advanced basal cell carcinoma (laBCC) per central review in the
sonidegib 800-mg arm (A) and per investigator review in the sonidegib 200-mg arm (B) and
800-mg arm (C). Best percentage change from baseline in the sum of the products of
perpendicular diameters in target lesion(s) assessed by photography per World Health
Organization criteria21 in the 800-mg arm (A) per central review and in the 200-mg arm (B)
and 800-mg arm (C) per investigator review. Tumor response was assessed by photography,
magnetic resonance imaging, and histology according to basal cell carcinomaemodified
Response Evaluation Criteria in Solid Tumors in patients with laBCC, and best overall response
is depicted by color. Assessments were excluded from the analysis if percentage change in the
size of target lesions was not available or was contraindicated by an overall lesion response of
unknown.
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Supplemental Fig 2. Waterfall plots of best change from baseline in the size of target lesions
in patients with metastatic basal cell carcinoma (mBCC) per central review in the sonidegib 200-
mg arm (A) and 800-mg arm (B) and per investigator review in the sonidegib 200-mg arm (C)
and 800-mg arm (D). Best percentage change from baseline in the sum of the longest diameters
in target lesion(s) assessed by all modalities used in the evaluations (ie, computed tomography
[CT ] or magnetic resonance imaging [MRI]) per Response Evaluation Criteria in Solid Tumors
v1.122 in the 200-mg arm (A) and 800-mg arm (B) per central review, and in the 200-mg arm (C)
and 800-mg arm (D) per investigator review. Tumor response was assessed by CT/MRI in
patients with mBCC, and best overall response is depicted by color. Assessments were
excluded from the analysis if percentage change in the size of target lesions was not available or
was contradicted by an overall lesion response of unknown.
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Supplemental Table I. Composite overall response in locally advanced basal cell carcinoma determined by
basal cell carcinomaemodified Response Evaluation Criteria in Solid Tumors
MRI* Photography Histologyz
Composite overall responsex
BCC-mRECIST
CR CR Negative CRz
PR (scar/fibrosis only) or SD (scar/fibrosis only) Negative
Not available Negative
Not available CR Negative CRz
PR (scar/fibrosis only) or SD (scar/fibrosis only) Negative
PR CR Negative PR
PR (scar/fibrosis only) or SD (scar/fibrosis only) Negative
SD CR Negative PR
PR (scar/fibrosis only) or SD (scar/fibrosis only) Negative
CR CR Positive or unknown PR
PR Any
PR (scar/fibrosis only) Positive or unknown
Not available
PR CR Positive or unknown PR
PR Any
PR (scar/fibrosis only) Positive or unknown
Not available Any
SD CR Positive or unknown PR
PR Any
PR (scar/fibrosis only) Positive or unknown
Not available CR Positive or unknown PR
PR Any
PR (scar/fibrosis only) Positive or unknown
CR SD Any SD
SD (scar/fibrosis only) Positive or unknown
PR SD Any SD
SD (scar/fibrosis only) Positive or unknown
SD SD Any SD
SD (scar/fibrosis only) Positive or unknown
Not available Any
Not available SD Any SD
SD (scar/fibrosis only) Positive or unknown
Any (except PD) Unknown Any Unknown
Unknown Any (except PD) Any Unknown
PD Any Any PD
Any PD Any PD
BCC, Basal cell carcinoma; CR, complete response; MRI, magnetic resonance imaging;mRECIST, modified Response Evaluation Criteria in Solid
Tumors; PD, progressive disease; PR, partial response; SD, stable disease.
*Per Response Evaluation Criteria in Solid Tumors v1.1.22
yPer World Health Organization criteria.21
zRequired multiple biopsy specimens based on lesion surface area.
xAn independent review committee re-evaluated all assessments for the locally advanced BCC cohort to determine a composite response.
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Supplemental Table II. Patient demographics and disease history by treatment
Baseline characteristic*
Sonidegib
200 mg once daily
n = 79
Sonidegib
800 mg once daily
n = 151
Age, median (range), y 67 (25-92) 65 (24-93)
Sex, male, n (%) 48 (60.8) 96 (63.6)
Race, n (%)
White 71 (89.9) 145 (96.0)
Other 8 (10.1) 6 (4.0)
Eastern Cooperative Oncology Group performance status, n (%)
0 50 (63.3) 95 (62.9)
1 19 (24.1) 44 (29.1)
2 8 (10.1) 10 (6.6)
Unknown 2 (2.5) 2 (1.3)
Predominant histologic/cytologic subtype for all patients based on case report forms, n (%)
Aggressivey 40 (50.6) 76 (50.3)
Nonaggressivez 38 (48.1) 68 (45.0)
Undetermined 1 (1.3) 6 (4.0)
Missing 0 1 (0.7)
Predominant histologic/cytologic subtype for patients with laBCC based
on randomization stratification, n (%)
n = 66 n = 128
Aggressivey 37 (56.1) 75 (58.6)
Nonaggressivez 29 (43.9) 53 (41.4)
Metastasis, n (%) 14 (17.7) 23 (15.2)
Metastatic sites, n (% of total with metastasis)
Lung 10 (71.4) 12 (52.2)
Lymph nodesx 1 (7.1) 7 (30.4)
Bone 2 (14.3) 5 (21.7)
Other// 3 (21.4) 7 (30.4)
Prior antineoplastic therapy, n (%)
Surgery 60 (75.9) 127 (84.1)
Radiotherapy 19 (24.1) 49 (32.5)
Reason for enrollment, n (%){
Multiple tumor recurrence after surgery or radiotherapy 15 (19.0) 47 (31.1)
Radiotherapy contraindicated because of preexisting condition 1 (1.3) 4 (2.6)
Surgery or radiotherapy inappropriate because of location of lesion 33 (41.8) 44 (29.1)
Severe disfigurement expected with surgical resection 25 (31.6) 43 (28.5)
Other 5 (6.3) 12 (7.9)
Missing 0 1 (0.7)
laBCC, Locally advanced basal cell carcinoma.
*Patients were evenly distributed between treatment arms (200 vs 800 mg) with regard to geographic region: Europe (57.0% vs 55.0%),
North America (36.7% vs 40.4%), and Australia (6.3% vs 4.6%).
yIncludes micronodular, infiltrative, multifocal, basosquamous, and sclerosing basal cell carcinoma.
zIncludes nodular and superficial basal cell carcinoma.
xIncludes axillary, parotid, submandibular, supraclavicular, and other.
//Includes trunk, brain, head, liver, neck, and upper extremities.
{Each patient enrolled provided only 1 reason.
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Supplemental Table III. Patient disposition
Parameter
200 mg
n = 79
800 mg
n = 151
All
N = 230
Patients randomized, n (%)
Treated 79 (100) 150 (99.3) 229 (99.6)
Untreated 0 1 (0.7) 1 (0.4)
Patients treated, n (%)
Treatment ongoing* 21 (26.6) 29 (19.2) 50 (21.7)
Treatment discontinued 58 (73.4) 121 (80.1) 179 (77.8)
Primary reason for treatment discontinuation, n (%)
Adverse event 20 (25.3) 52 (34.4) 72 (31.3)
Patient decisiony 7 (8.9) 29 (19.2) 36 (15.7)
Progressive diseasez 23 (29.1) 15 (9.9) 38 (16.5)
Physician decisiony 7 (8.9) 11 (7.3) 18 (7.8)
Loss to follow-up 1 (1.3) 4 (2.6) 5 (2.2)
Death 0 5 (3.3) 5 (2.2)
Nonadherence 0 4 (2.6) 4 (1.7)
Protocol deviation 0 1 (0.7) 1 (0.4)
Study evaluation after end of treatment phase
Patients continued to the next phase of the trial, n (%) 42 (53.2) 72 (47.7) 114 (49.6)
Posttreatment follow-up 17 (21.5) 36 (23.8) 53 (23.0)
Survival follow-up 25 (31.6) 36 (23.8) 61 (26.5)
*Patients ongoing at the time of the 12-mo analysis (data cutoff: December 31, 2013).
yDecisions to withdraw by patient or physician were mostly because of adverse events.
zMore patients in the 200-mg arm were able to remain on treatment until disease progression because of improved tolerability.
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